Study of NGX-4010 for the Treatment of Painful HIV-Associated Neuropathy (HIV-AN) or Postherpetic Neuralgia (PHN)
Status:
Completed
Trial end date:
2006-12-01
Target enrollment:
Participant gender:
Summary
The purpose of the study is to evaluate the safety and efficacy of NGX-4010 administered at
intervals of no less than 12 weeks over 1 year, based on the presence or return of pain, for
the treatment of painful HIV-AN and PHN. Participation is limited to former study subjects
from previous trials of NGX-4010 at selected sites.